Alkermes (ALKS) Income from Non-Controlling Interests (2011 - 2012)
Alkermes' (ALKS) quarterly Income from Non-Controlling Interests came in at $594000.0 in Q3 2012, up 343.44% year-on-year from $133951.9 in Q4 2011, and up 343.44% on a QoQ basis from -$244000.0 in Q3 2011.
Alkermes (ALKS) Income from Non-Controlling Interests (2011 - 2012) Analysis & Trends
Alkermes (ALKS) has 2 years of Income from Non-Controlling Interests data on file, last reported at $594000.0 in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 594,000.00 |
| Sep 30, 2011 | -244,000.00 |